Foreign Pharmas Seek To Fill Japan Vacuum For Antibody Drugs
This article was originally published in PharmAsia News
Executive Summary
The lack of antibody drugs marketed by Japanese drug makers is leading foreign pharmas to put their own versions on the market in Japan. Novartis AG is expected to be the first foreign firm to enter the market by the end of the year, with its Xolair (omalizumab) for treating asthma. Companies expected to follow Novartis to the market soon after include Bristol-Myers Squibb and Merck Serono International with their Erbitux (cerbitux) colon cancer drug. Other firms are holding clinical trials in Japan for drug candidates. (Click here for more - a subscription may be required